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OBJECTIVE: To examine the degree of association between
medical conditions and work-loss and to estimate the costs asso-
ciated with work absenteeism among workers in US during
2001. METHODS: Data were extracted from the 2001 Medical
Expenditure Panel Survey, a nationally representative survey of
medical care use and expenditures conducted by the Agency for
Healthcare Research and Quality. The study sample included
heads of household, 23–65 years old, who were employed for
the entire year (not self employed). Of interest was the incidence
of work loss during 2001. Additional information was collected
on number of work days lost during the year, the associated
medical conditions based on ICD-9-CM codes and other demo-
graphic and employment characteristics. Logistic regression was
used to assess association of medical conditions with work
absenteeism controlling for other characteristics. RESULTS: In
total, 4687 persons were identiﬁed. Mean age was 40.6 years,
54.4% were male, 18.8% were non-white, and 51.2% had at
least high-school education. Workers earned on average $16.8
per-hour, and worked 41.5 hours-per-week. Work loss was
reported by 2614 persons (55.8%), who on the average lost 8.5
work-days per year (median 3.3 days), valued at $1069 based
on reported hourly wages (median $365). After adjusting for
other demographic and employment characteristics, logistic
regression analysis revealed that medical conditions were signif-
icant predictors of absenteeism. Speciﬁcally (odds ratio; 95%
conﬁdence intervals): infectious diseases (5.0; 4.1–6.2), mental
disorders (1.6; 1.3–2.0), respiratory system (3.3; 2.9–3.8), diges-
tive system (2.5; 2.0–3.1), and musculoskeletal system (1.8;
1.6–2.2). Absenteeism was more likely to be reported among
females (1.4; 1.3–1.7) and those with sick beneﬁts (1.3; 1.1–1.5).
CONCLUSION: Medical conditions are signiﬁcant predictors of
work loss and associated costs. To reduce incidence and costs
associated with work loss, effective policies would need to
address the use of effective disease prevention measures and
chronic disease treatments.
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OUTCOMES OF TECHNOLOGY APPLICATION ON
PHARMACISTS JOB PERFORMANCE: THE ROLE OF
PERSONAL DIGITAL ASSISTANTS
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OBJECTIVE: The objective of this study was to evaluate the out-
comes associated with the use of Personal Digital Assistants
(PDAs) by pharmacists’ working in retail and hospital setting
using Extended Technology Acceptance Model (ETAM).
METHODS: A cross-sectional study was conducted by admin-
istering a survey to pharmacists (N = 285, Retail = 138, Hospi-
tal = 147) in the Houston metropolitan area. A prevalidated
questionnaire using thirty items, ﬁve-point strongly disagree
(1)—strongly agree (5) Likert scale was used to measure phar-
macists’ perceived usefulness and intention to use PDAs. Data
along with demographic information such as age, gender, edu-
cation, income and practice setting were collected, coded, and
analyzed using SAS at a set priori signiﬁcance level of 0.05.
Descriptive, correlation and stepwise regression analyses were
performed to predict pharmacists’ intention to use PDAs.
RESULTS: Among the surveyed population only 35% of retail
pharmacists’ owned a PDA in comparison to 64% of hospital
pharmacists’. Overall, pharmacists’ in both retail and hospital
settings indicated that PDAs’ can improve job efﬁciency (55%)
and be a cost effective tool (63%) in providing patient care.
Further, spearman correlation analysis indicated high correlation
between perceived usefulness and intention to use PDAs in hos-
pital setting (r = 0.78, p < 0.001). However, in retail setting result
demonstrability, tangibility and communicability of the results
associated with the use of PDAs’ was highly correlated with
intention to use (r = 0.62, p < 0.001). ETAM was able to explain
55% and 71% of variance in retail and hospital pharmacists’
intention to use PDAs respectively. CONCLUSIONS: The ETAM
model, speciﬁcally, variables such as perceived usefulness, atti-
tude, and result demonstrability were useful in predicting phar-
macist’s intention to use PDAs in both the settings. As technology
advances, PDAs would provide pharmacists’ an affective tool for
improving efﬁciency in job and subsequently the patient care
related outcomes.
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EXAMINING THE QUALITY OF HEALTH ECONOMIC
ANALYSES SUBMITTED TO THE PHARMACEUTICAL
BENEFITS BOARD IN SWEDEN.—DATA FROM THE FIRST 
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OBJECTIVES: To assess the quality of the health economic
material submitted to the Swedish Pharmaceutical Beneﬁts Board
(PBB) as part of the application for reimbursement for new phar-
maceuticals. The cost per QALY in the submitted material and
how this has related to the PBB’s decision is also presented.
METHODS: The health economic evaluations were reviewed
independently by two reviewers against two check lists, marking
each question Yes/No/Not Applicable. The checklists used were:
1) The PBB Guidelines transformed into yes or no questions and
2) The QHES check list, which is a validated instrument. The
central estimate, or base case, cost effectiveness was collected
(preferably cost per QALY) as well as whether the application
was accepted or rejected by the PBB. RESULTS: The scores on
the PBB check list range from 0.24 to 0.87 and on the QHES
from 0.09 to 1, with a mean quality of 0.61 and 0.67 respec-
tively. Due to Swedish-speciﬁc criteria in the PBB list, there is
only a modest correlation between the two instruments of 0.7.
The baseline cost per QALY in the applications range from neg-
ative values (i.e. a cost-saving drug) to approximately 65,000
Euros. There was a low observed correlation between quality
score and acceptance by the PBB. Likewise, the correlation
between cost per QALY and decision to accept/reject is low or
non-existent. CONCLUSIONS: 1) Health economic material as
part of applications to PBB varies heavily in quality. 2) Due to
the relatively small number of applications supported by sub-
stantial health economic evidence and the even fewer rejections,
it is difﬁcult to draw ﬁrm conclusions regarding the value the
PBB places on a QALY.
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OBJECTIVES: Introduction of a compulsory economic evalua-
tion policy for pharmaceutical reimbursement was enacted in
Korea in 2000, but has yet to be fully implemented. Concerns
about the quality and availability of population speciﬁc clinical
data, treatment patterns, health care prices and subsequent 
cost-effectiveness data have been raised. We evaluated the quality
of Korean economic evaluation studies of pharmaceuticals to
understand gaps. From this, we propose policy options that
might strengthen the research infrastructure in order to support
such studies. METHODS: We reviewed 21 published studies of
drugs conducted between 1996 and 2004. We utilized a pub-
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lished algorithm to assess quality. Evaluation criteria included
methodological characteristics (perspective, selection of com-
parators, and modeling framework), health care system charac-
teristics (relevance and applicability of clinical, treatment pattern
and cost data), population characteristics (generalizability), and
implications. RESULTS: Large variation in study quality was
observed, particularly with outcome data and treatment pat-
terns. We found that data on the effectiveness of drugs was typ-
ically extracted from clinical trials that did not include an Asian
population, used inappropriate comparators and involved prac-
tice patterns that were not consistent with standards of care in
Korea. With respect to treatment patterns, the most frequent sit-
uation relied on expert opinion from academic physicians in spe-
cialty practice. The Korean National Health Insurance Claims
Database was a good source of disease speciﬁc costs, but was
rarely used. Furthermore, the database failed to capture non-
covered services. Preference measures, when used, were not
elicited from the Korean population. Most studies (80%) did not
clarify the funding source. CONCLUSIONS: If the Korean eco-
nomic evaluation policy is to provide meaningful data for deci-
sion makers, the quality of cost-effectiveness studies will need 
to improve dramatically. This may involve access to or creation
of better data, more diverse funding, improved training of
researchers and evaluators, and partnerships with technology
manufacturers.
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OBJECTIVES: To implement a computerized, centralized, drug
prior-authorization process in a national managed care organi-
zation to control utilization and expenditures of expensive 
medications and to ensure uniformity of authorization criteria
throughout the organization. METHODS: This program was
implemented in the Leumit Health Fund, a HMO operating in
Israel. The HMO’s Medical Division has formulated a drug
policy mandating prior-approval by the Central Medicines
Department for expensive drugs. Additionally, these products
may only be dispensed from HMO owned and operated phar-
macies. To expedite this authorization process, a special com-
puter program was developed which operates under the HMO’s
electronic patient record (EPR) system. Upon prescribing one of
these drugs, a window automatically appears instructing the
physician to press a function key for transmission of an autho-
rization request to the Medical Division for approval of HMO
coverage. Two lines are provided to enter supplementary infor-
mation. The patient is then given a computer-generated pre-
scription which prior to approval, cannot be dispensed via the
HMO’s pharmacy dispensing program which is integrated with
the EPR. The distribution of drugs requested by class, and pro-
portion of requests rejected for the year 2003 was evaluated. The
aggregate monetary value of the requests denied was evaluated.
RESULTS: Throughout the year 2003, 38,490 requests were 
submitted, 44.88% of which were denied. The distribution 
of requests by drug or drug class was: Antineoplastic and
immunomodulating agents 15.58%; neurologicals (not including
anti-epileptics) 14%; newer insulins and rosiglitazone 12%;
ocular lubricants (for patients not suffering from FD or CF)
10.55%; angiotensin receptor blockers 10.24%; clopidogrel
7.18%; other 30.45%. The annual aggregate potential cost of
requests denied was 82,771,608 New Israel Shekels (1 NIS = 4.6
USD). Requests for antineoplastic and immunomodulating
agents accounted for 36.37% of this sum. CONCLUSIONS: The
system was successfully implemented and facilitated standard-
ized approval criteria on the national level.
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OBJECTIVES: To empirically develop and validate the RxCost
Model, a prospective and concurrent risk assessment model that
uses claims-based diagnostic information to predict future phar-
macy expenditures for a US commercial population. Addition-
ally, we sought to empirically develop, validate, and compare the
Mixed RxCost (MRxCost) Model to explore the gain in predic-
tive power associated with adding drug information to the
RxCost Model. Prescription cost risk assessment models can be
used to proﬁle physician practices or control for comorbidity
burden in economic studies. METHODS: A retrospective longi-
tudinal cohort study using MEDSTAT MarketScan claims data
(1998–2000) for ambulatory persons who were continuously
enrolled for at least 13 months and were 18 to 64 years old was
used. A training sample consisting of over 1.3 million lives was
utilized to develop the models. Model coefﬁcients were devel-
oped from AHRQ clinical classiﬁcation software, clinical expert
panel, and stepwise OLS regression to screen noise variables. A
random holdout sample of 218,383 was utilized to validate the
models and to compare the performance of each model. Measure
of discrimination (R-squared), predictive ratios, and discrimina-
tion for hypothetical physician groups were computed and com-
pared to each other as well as to a Demographic-only model and
the proprietary DCG-HCC model. RESULTS: The R-square
value for the prospective RxCost, the MRxCost Model and the
DCG-HCC using the validation sample was 0.22, 0.34 and 0.16,
respectively and was 0.34 for the concurrent RxCost model. The
RxCost model’s predictive ratio’s varied between 0.93 and 1.05
for clinical subgroups and ranged from 1.03 to 1.04 across hypo-
thetical physician patient groups of size 10 to 500. CONCLU-
SIONS: The RxCost Model was successfully developed and it
outperformed the DCG-HCC model in terms of R-square after
re-calibrating the DCG-HCC model. The MRxCost Model also
proved that supplementing drug information can improve dis-
criminatory power.
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OBJECTIVES: To develop key performance indicators for the
Australian reimbursement system and to facilitate ongoing
analysis of the drug funding environment. METHODS: This
study involved the establishment of a relational database that
captured all relevant data over a 14-year period. This included
details of the Australian Pharmaceutical Beneﬁts Advisory Com-
mittee recommendations, listing criteria, product type, pricing,
type of economic evaluation, and public expenditure by product
type. A series of pricing indexes was also developed. The key
performance indicators are in the process of being developed
with input from industry and Government. These objectives are
consistent with the goals of the Free Trade Agreement between
Australia and the USA. RESULTS: The key performance indica-
